Advances in management and treatment of tubercular meningitis – a narrative review

Author:

Malik Manal Arshad1,Kamran Aleena2,Ahsan Dua3ORCID,Amjad Aafia4ORCID,Moatter Sara5,Noor Amna4ORCID,Sohaib Asharib6ORCID,Shaukat Maryam7ORCID,Masood Waniyah6,Hasanain Muhammad8ORCID,Mahmmoud Fadelallah Eljack Mohammed9ORCID

Affiliation:

1. Liaquat National Hospital, Karachi, Pakistan

2. Jinnah Medical and Dental College, Karachi, Pakistan

3. Sir Syed College of Medical Sciences, Karachi, Pakistan

4. Isra University, Hyderabad, Pakistan

5. Sindh Medical College, Jinnah Sindh Medical University, Karachi, Pakistan

6. Dow Medical College, Dow University of Health Sciences, Karachi, Pakistan

7. Aga Khan University, Karachi, Pakistan

8. Dow University of Health Sciences, Karachi, Pakistan

9. Community Department, University of Bakht Alruda, Ad Duwaym, Sudan

Abstract

Background: Tuberculosis (TB), caused by Mycobacterium tuberculosis, continues to be a major global health issue, particularly due to its potential to cause severe complications such as tubercular meningitis (TBM), which is a fatal condition that proves difficult to diagnose and treat effectively and often results in poor outcomes, especially in children, due to delayed diagnosis, drug resistance, and limited diagnostic techniques. Methods: This review provides a comprehensive overview of recent advancements in TBM management and treatment. A systematic search was performed across major databases, including PubMed, Google Scholar, ClinicalTrials.gov, the WHO International Clinical Trials Registry Platform, and the ISRCTN Registry. The search strategy used terms like (“tubercular meningitis” OR “TBM” OR “TB meningitis”) AND (“diagnosis” OR “treatment” OR “clinical trials”). Inclusion criteria focused on studies published from January 2014 to September 2024, highlighting novel diagnostics, therapeutic advances, and clinical trials for TBM. Exclusion criteria involved studies unrelated to TBM or older than 10 years. Results: Diagnostic methods for TBM, such as microbiological and molecular techniques (Fig. 1), vary in sensitivity, with polymerase chain reaction assays being the most sensitive. While anti-TB drugs are available, drug resistance and poor cerebrospinal fluid penetration limit effectiveness. New molecular diagnostics and therapies, including anti-TNF agents, anti-inflammatory drugs, and antibiotics, show promise for improving outcomes. JOURNAL/amsur/04.03/01845215-202506000-00069/figure1/v/2025-06-12T194953Z/r/image-jpeg Conclusion: Despite recent advancements in TBM diagnostics and treatment, substantial challenges remain, particularly in addressing drug resistance and improving drug efficacy in the central nervous system. Continued innovation in molecular diagnostics and treatment approaches is essential to enhance TBM care and mitigate its devastating consequences.

Publisher

Ovid Technologies (Wolters Kluwer Health)

Reference43 articles.

1. History of pulmonary tuberculosis;Pezzella;Thorac Surg Clin,2019

2. Tuberculosis: a disease without boundaries;Fogel;Tuberc Edinb Scotl,2015

3. Extrapulmonary tuberculosis;Ramírez-Lapausa;Rev Esp Sanid Penit,2015

4. Tuberculous meningitis;Wilkinson;Nat Rev Neurol,2017

5. The global burden of tuberculous meningitis in adults: a modelling study;Dodd;PLOS Glob Public Health,2021

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.7亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2025 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3